Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-667-4085
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees20
Next Earnings Date2/5/2020 (Estimated)
OptionableNot Optionable
Mirum Pharmaceuticals (NASDAQ:MIRM) Frequently Asked Questions
What is Mirum Pharmaceuticals' stock symbol?
Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."
How were Mirum Pharmaceuticals' earnings last quarter?
Mirum Pharmaceuticals (NASDAQ:MIRM) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.84) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.25. View Mirum Pharmaceuticals' Earnings History.
When is Mirum Pharmaceuticals' next earnings date?
What price target have analysts set for MIRM?
5 brokerages have issued 1-year price targets for Mirum Pharmaceuticals' shares. Their forecasts range from $18.00 to $33.00. On average, they anticipate Mirum Pharmaceuticals' stock price to reach $25.00 in the next year. This suggests a possible upside of 239.2% from the stock's current price. View Analyst Price Targets for Mirum Pharmaceuticals.
What is the consensus analysts' recommendation for Mirum Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirum Pharmaceuticals.
Has Mirum Pharmaceuticals been receiving favorable news coverage?
News coverage about MIRM stock has trended very negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mirum Pharmaceuticals earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Mirum Pharmaceuticals.
Are investors shorting Mirum Pharmaceuticals?
Mirum Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 62,800 shares, an increase of 65.3% from the September 30th total of 38,000 shares. Based on an average trading volume of 44,200 shares, the days-to-cover ratio is presently 1.4 days. Approximately 1.3% of the shares of the stock are sold short. View Mirum Pharmaceuticals' Current Options Chain.
Who are some of Mirum Pharmaceuticals' key competitors?
Some companies that are related to Mirum Pharmaceuticals include Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), Akorn (AKRX), OrganiGram (OGI), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), DiaMedica Therapeutics (DMCAF), ChemoCentryx (CCXI), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Synthorx (THOR) and BioDelivery Sciences International (BDSI).
What other stocks do shareholders of Mirum Pharmaceuticals own?
Who are Mirum Pharmaceuticals' key executives?
Mirum Pharmaceuticals' management team includes the folowing people:
- Mr. Michael G. Grey, Exec. Chairman (Age 66)
- Mr. Christopher Peetz, Pres, CEO & Director (Age 40)
- Dr. Ian Clements, Sr. VP of Fin. & Communications (Age 50)
- Dr. Pamela Vig Ph.D., Chief Scientific Officer (Age 48)
- Ms. Lara Longpre MSC, MBA, Chief Devel. Officer (Age 49)
When did Mirum Pharmaceuticals IPO?
(MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.
When does the company's lock-up period expire?
Mirum Pharmaceuticals' lock-up period expires on Tuesday, January 14th. Mirum Pharmaceuticals had issued 5,000,000 shares in its public offering on July 18th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
Who are Mirum Pharmaceuticals' major shareholders?
Mirum Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dean Capital Investments Management LLC (0.20%). Company insiders that own Mirum Pharmaceuticals stock include Christopher Peetz, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig and Patrick J Heron. View Institutional Ownership Trends for Mirum Pharmaceuticals.
Which major investors are buying Mirum Pharmaceuticals stock?
MIRM stock was purchased by a variety of institutional investors in the last quarter, including Dean Capital Investments Management LLC. Company insiders that have bought Mirum Pharmaceuticals stock in the last two years include Christopher Peetz, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig and Patrick J Heron. View Insider Buying and Selling for Mirum Pharmaceuticals.
How do I buy shares of Mirum Pharmaceuticals?
Shares of MIRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mirum Pharmaceuticals' stock price today?
One share of MIRM stock can currently be purchased for approximately $7.37.
How big of a company is Mirum Pharmaceuticals?
What is Mirum Pharmaceuticals' official website?
How can I contact Mirum Pharmaceuticals?
Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company can be reached via phone at 650-667-4085 or via email at [email protected]
MarketBeat Community Rating for Mirum Pharmaceuticals (NASDAQ MIRM)
MarketBeat's community ratings are surveys of what our community members think about Mirum Pharmaceuticals and other stocks. Vote "Outperform" if you believe MIRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MIRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
